Tissue Regenix announces that it has signed an exclusive distribution agreement with Kingsung Medical Group (Kingsung Medical), a Hong Kong-based medical enterprise, for the distribution of OrthoPure® XT in China. The initial agreement is for six years and requires Kingsung Medical to purchase a minimum unit volume each year to maintain its exclusive status. As part of the agreement, Kingsung Medical and Tissue Regenix are mutually committed to advancing the clinical study of OrthoPure® XT to further support the regulatory approval process in China.Kingsung Medical isa medical technology group that integrates production, development and sales to provide medical technologies with exclusive value and service.

It has direct sales teams in 10 cities in China as well as channel marketing sales and agents in every province to support clinics. The OrthoPure®XT decellularised xenograft ligament utilises Tissue Regenix's patented dCELL® technology and is the only available, non-human biologic graft indicated for certain ligament reconstruction procedures. The CE-marked OrthoPure®XT can be used for the revision of anterior cruciate ligament (ACL) reconstruction procedures and reconstruction of other knee ligaments, includingmulti-ligamentand primary procedures when an autograft is not an option.